To assess the prognostic relevance of gene signatures, we conducted a survival analysis and found that CRC cohorts with higher expression profiles of c-Met and cohorts with lower expression profiles of EGFR exhibited low survival rates (Figure 1G) and resistance to oxaliplatin chemotherapy. The gene discussed is MET; the disease is colorectal carcinoma.